KPIs & Operating Metrics(New)
Aesthetics Revenue By CategoryAesthetics Revenue By Category AnnualAesthetics Revenue By GeographyAesthetics Revenue By Geography AnnualBreakdown Of AssetsEmployee StatisticsEye Care Revenue By CategoryEye Care Revenue By Category AnnualEye Care Revenue By GeographyEye Care Revenue By Geography AnnualGross MarginGross Margin %Gross Margin AnnualGross Margin Annual %Hematology Oncology Revenue By CategoryHematology Oncology Revenue By Category AnnualHematology Oncology Revenue By GeographyHematology Oncology Revenue By Geography AnnualImmunology Revenue By CategoryImmunology Revenue By Category AnnualImmunology Revenue By GeographyImmunology Revenue By Geography AnnualIncome Before Income Taxes By RegionLong Lived Assets By RegionNeuroscience Revenue By CategoryNeuroscience Revenue By Category AnnualNeuroscience Revenue By GeographyNeuroscience Revenue By Geography AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Opex As A % Of RevenueOPEX SegregationOther Key Products Revenue By CategoryOther Key Products Revenue By Category AnnualOther Key Products Revenue By GeographyOther Key Products Revenue By Geography AnnualProperty & Equipment BreakdownRevenueRevenue By GeographyRevenue By Geography %Revenue By Geography AnnualRevenue By Geography Annual %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Revenue By Ship To LocationRevenue By Ship To Location %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AbbVie (ABBV) Revenue (2012 - 2026)

AbbVie (ABBV) reported Revenue of $15.0 billion for Q1 2026, up 12.43% year-over-year from $13.3 billion in Q1 2025, and down 9.72% on a QoQ basis from $16.6 billion in Q4 2025.

AbbVie (ABBV) has 15 years of Revenue data on file, last reported at $15.0 billion in Q1 2026.

  • Quarterly Revenue rose 12.43% year-over-year to $15.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $62.8 billion (up 9.5% YoY) and the FY2025 annual result came in at $61.2 billion, up 8.57% from the prior year.
  • Revenue eased to $15.0 billion in Q1 2026 per ABBV's latest filing, from $16.6 billion in the prior quarter.
  • Across five years, Revenue topped out at $16.6 billion in Q4 2025 and bottomed at $12.2 billion in Q1 2023.
  • The 5-year median for Revenue is $14.5 billion (2024), against an average of $14.4 billion.
  • The widest annual swing landed in 2023, when Revenue dropped 9.7%; it then increased 12.43% in 2026.
  • Tracing ABBV's Revenue over 5 years: stood at $15.1 billion in 2022, then retreated by 5.42% to $14.3 billion in 2023, then gained by 5.6% to $15.1 billion in 2024, then grew by 10.04% to $16.6 billion in 2025, then dropped by 9.72% to $15.0 billion in 2026.
  • Per Business Quant, the three latest ABBV Revenue figures stand at $15.0 billion (Q1 2026), $16.6 billion (Q4 2025), and $15.8 billion (Q3 2025).